Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Michael Albeck"'
supplemental materials and supplemental figure legends for publication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d537d2a97f18ca2c147c451ba59c610
https://doi.org/10.1158/1541-7786.22517496
https://doi.org/10.1158/1541-7786.22517496
Supplemental Figure S3. The T127 and Jurkat human T leukemic cells that do not secrete IL-10 are not sensitized by AS101 to Paclitaxel-induced death.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a15cf6311efc7103f984bb1472c41e3
https://doi.org/10.1158/1541-7786.22517502.v1
https://doi.org/10.1158/1541-7786.22517502.v1
Supplemental Figure S2. AS101 sensitizes breast carcinoma MCF-7 cells to Abraxane-induced death.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7339ae8585001cf9bf7ec90633e5313e
https://doi.org/10.1158/1541-7786.22517505
https://doi.org/10.1158/1541-7786.22517505
Supplemental Figure S4: Chemoresistance of NHL cells induced by BM Stromal cells is abrogated by AS101.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ebf04061f4be4b0cabddb00e505bb4
https://doi.org/10.1158/1541-7786.22517499
https://doi.org/10.1158/1541-7786.22517499
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
PDF file - 766K, Fig. S2: Chemoresistance of myelomonocytic leukemia cells induced by BM Stromal cells is abrogated by AS101.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32578aa034dc7b555d9b3ec6b8972914
https://doi.org/10.1158/0008-5472.22400336
https://doi.org/10.1158/0008-5472.22400336
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
PDF file - 1318K, Fig S4. DTNB or AS101 sensitize high VLA-4 expressing lekemic cells from AML patients, to chemotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a1f1086fa643b75c8f4a45f4e78d15b
https://doi.org/10.1158/0008-5472.22400330.v1
https://doi.org/10.1158/0008-5472.22400330.v1
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
PDF file - 129K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5241285e6927d0c444aa93dc9f36706a
https://doi.org/10.1158/0008-5472.22400318.v1
https://doi.org/10.1158/0008-5472.22400318.v1
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
PDF file - 1086K, Fig. S5: Knocking out VLA-4 in mouse myelomonocytic leukemia cells or human AML leukemic cells induces drug sensitivity which is not further enhanced by AS101.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0461c693b69c0a18d52b59abfec84327
https://doi.org/10.1158/0008-5472.22400327.v1
https://doi.org/10.1158/0008-5472.22400327.v1
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
PDF file - 981K, Fig. S6: Inhibition of pAkt mediates AS101's activity involving chemotherapy-induced AML cell death as tested by subG1 accumulation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::246da1d8e8a5f6b817697d33028c877b
https://doi.org/10.1158/0008-5472.22400324.v1
https://doi.org/10.1158/0008-5472.22400324.v1
Autor:
Benjamin Sredni, Yona Kalechman, Dan L. Longo, Michael Albeck, Alon Silberman, Elad Noy, Maor H. Pauker, Alain Berrebi, Itai Skornick, Adi Layani-Bazar
Interaction between the integrin VLA-4 on acute myelogenous leukemia (AML) cells with stromal fibronectin is a decisive factor in chemotherapeutic resistance. In this study, we provide a rationale for a drug repositioning strategy to blunt integrin a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d0bb3743cdb83831c5ae03c53331db0
https://doi.org/10.1158/0008-5472.c.6505562
https://doi.org/10.1158/0008-5472.c.6505562